Cargando…

Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures

BACKGROUND: Litigation documents reveal that pharmaceutical companies have paid physicians to promote off-label uses of their products through a number of different avenues. It is unknown whether physicians and scientists who have such conflicts of interest adequately disclose such relationships in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kesselheim, Aaron S., Wang, Bo, Studdert, David M., Avorn, Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413710/
https://www.ncbi.nlm.nih.gov/pubmed/22899894
http://dx.doi.org/10.1371/journal.pmed.1001280
_version_ 1782240105058009088
author Kesselheim, Aaron S.
Wang, Bo
Studdert, David M.
Avorn, Jerry
author_facet Kesselheim, Aaron S.
Wang, Bo
Studdert, David M.
Avorn, Jerry
author_sort Kesselheim, Aaron S.
collection PubMed
description BACKGROUND: Litigation documents reveal that pharmaceutical companies have paid physicians to promote off-label uses of their products through a number of different avenues. It is unknown whether physicians and scientists who have such conflicts of interest adequately disclose such relationships in the scientific publications they author. METHODS AND FINDINGS: We collected whistleblower complaints alleging illegal off-label marketing from the US Department of Justice and other publicly available sources (date range: 1996–2010). We identified physicians and scientists described in the complaints as having financial relationships with defendant manufacturers, then searched Medline for articles they authored in the subsequent three years. We assessed disclosures made in articles related to the off-label use in question, determined the frequency of adequate disclosure statements, and analyzed characteristics of the authors (specialty, author position) and articles (type, connection to off-label use, journal impact factor, citation count/year). We identified 39 conflicted individuals in whistleblower complaints. They published 404 articles related to the drugs at issue in the whistleblower complaints, only 62 (15%) of which contained an adequate disclosure statement. Most articles had no disclosure (43%) or did not mention the pharmaceutical company (40%). Adequate disclosure rates varied significantly by article type, with commentaries less likely to have adequate disclosure compared to articles reporting original studies or trials (adjusted odds ratio [OR] = 0.10, 95%CI = 0.02–0.67, p = 0.02). Over half of the authors (22/39, 56%) made no adequate disclosures in their articles. However, four of six authors with ≥25 articles disclosed in about one-third of articles (range: 10/36–8/25 [28%–32%]). CONCLUSIONS: One in seven authors identified in whistleblower complaints as involved in off-label marketing activities adequately disclosed their conflict of interest in subsequent journal publications. This is a much lower rate of adequate disclosure than has been identified in previous studies. The non-disclosure patterns suggest shortcomings with authors and the rigor of journal practices. Please see later in the article for the Editors' Summary
format Online
Article
Text
id pubmed-3413710
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34137102012-08-16 Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures Kesselheim, Aaron S. Wang, Bo Studdert, David M. Avorn, Jerry PLoS Med Research Article BACKGROUND: Litigation documents reveal that pharmaceutical companies have paid physicians to promote off-label uses of their products through a number of different avenues. It is unknown whether physicians and scientists who have such conflicts of interest adequately disclose such relationships in the scientific publications they author. METHODS AND FINDINGS: We collected whistleblower complaints alleging illegal off-label marketing from the US Department of Justice and other publicly available sources (date range: 1996–2010). We identified physicians and scientists described in the complaints as having financial relationships with defendant manufacturers, then searched Medline for articles they authored in the subsequent three years. We assessed disclosures made in articles related to the off-label use in question, determined the frequency of adequate disclosure statements, and analyzed characteristics of the authors (specialty, author position) and articles (type, connection to off-label use, journal impact factor, citation count/year). We identified 39 conflicted individuals in whistleblower complaints. They published 404 articles related to the drugs at issue in the whistleblower complaints, only 62 (15%) of which contained an adequate disclosure statement. Most articles had no disclosure (43%) or did not mention the pharmaceutical company (40%). Adequate disclosure rates varied significantly by article type, with commentaries less likely to have adequate disclosure compared to articles reporting original studies or trials (adjusted odds ratio [OR] = 0.10, 95%CI = 0.02–0.67, p = 0.02). Over half of the authors (22/39, 56%) made no adequate disclosures in their articles. However, four of six authors with ≥25 articles disclosed in about one-third of articles (range: 10/36–8/25 [28%–32%]). CONCLUSIONS: One in seven authors identified in whistleblower complaints as involved in off-label marketing activities adequately disclosed their conflict of interest in subsequent journal publications. This is a much lower rate of adequate disclosure than has been identified in previous studies. The non-disclosure patterns suggest shortcomings with authors and the rigor of journal practices. Please see later in the article for the Editors' Summary Public Library of Science 2012-08-07 /pmc/articles/PMC3413710/ /pubmed/22899894 http://dx.doi.org/10.1371/journal.pmed.1001280 Text en © 2012 Kesselheim et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kesselheim, Aaron S.
Wang, Bo
Studdert, David M.
Avorn, Jerry
Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
title Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
title_full Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
title_fullStr Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
title_full_unstemmed Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
title_short Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
title_sort conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413710/
https://www.ncbi.nlm.nih.gov/pubmed/22899894
http://dx.doi.org/10.1371/journal.pmed.1001280
work_keys_str_mv AT kesselheimaarons conflictofinterestreportingbyauthorsinvolvedinpromotionofofflabeldruguseananalysisofjournaldisclosures
AT wangbo conflictofinterestreportingbyauthorsinvolvedinpromotionofofflabeldruguseananalysisofjournaldisclosures
AT studdertdavidm conflictofinterestreportingbyauthorsinvolvedinpromotionofofflabeldruguseananalysisofjournaldisclosures
AT avornjerry conflictofinterestreportingbyauthorsinvolvedinpromotionofofflabeldruguseananalysisofjournaldisclosures